TITLE

Clobetasol

PUB. DATE
August 2013
SOURCE
Reactions Weekly;8/24/2013, Issue 1466, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
An abstract of the article "Human papillomavirus reactivation following treatment of genital graft-versus-host disease," by T. Sri and colleagues is presented.
ACCESSION #
89895166

 

Related Articles

  • Ciclosporin.  // Reactions Weekly;02/16/2013, Issue 1439, p10 

    The article presents a case study of a 10-year-old boy who developed posterior reversible encephalopathy syndrome (PRES) while receiving ciclosporin as graft versus host disease (GVHD) prophylaxis following allogeneic bone marrow transplantation for acute lymphocytic leukaemia.

  • Ciclosporin.  // Reactions Weekly;6/27/2009, Issue 1258, p11 

    The article describes the case of a 51-year-old man with acute lymphocytic leukaemia who underwent allogenic stem cell transplantation. The patient received ciclosporin 3 milligrams/kilograms/day for graft-versus-host disease prophylaxis. He developed rest tremor and reduced facial expression...

  • ARIAD'S GENE-TARGETED DRUG GRANTED ORPHAN DRUG STATUS.  // Biotech Business;Apr2000, Vol. 13 Issue 4, p2 

    Reports that ARIAD Pharmaceuticals Incorporated's gene-targeted drug has been granted an orphan drug status for the treatment of acute graft-versus-host disease by the Food and Drug Administration in April 2000.

  • Advances in the treatment of graft-versus-host disease. Vogelsang, G B // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p509 

    Graft-versus-host disease (GVHD) is a complicated disease whose treatment requires an equally multifaceted approach. Recipient conditioning, donor T cell activation, and end stage effectors all may be potential targets for treatment. Many drugs used in the past are returning to the forefront for...

  • Posaconazole Prophylaxis in Hematologic Cancer. Weiler, Stefan; Bellmann, Romuald // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. Kontoyiannis, Dimitrios P.; Lewis, Russell E. // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. Krause, David S. // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. van Nieuwkoop, Cees; van Dissel, Jaap T. // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. Ullmann, Andrew J.; Chandrasekar, Pranatharthi; Patino, Hernando // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a reply to letters to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics